{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:29:35Z","timestamp":1786404575838,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54466-4","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:56:57Z","timestamp":1780142217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors and outcomes of hepatic decompensation following transarterial locoregional therapy in hepatocellular carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Faisal M.","family":"Sanai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Saati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdan","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Aldosari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Alzanbagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Albenmousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid I.","family":"Bzeizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Abaalkhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar","family":"AlJudaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"1","key":"54466_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 7(1), 6 (2021).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"Suppl 1","key":"54466_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.4103\/sjg.SJG_477_20","volume":"26","author":"SA Alqahtani","year":"2020","unstructured":"Alqahtani, S. A. et al. Saudi association for the study of liver diseases and transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J. Gastroenterol. 26(Suppl 1), S1\u2013S40 (2020).","journal-title":"Saudi J. Gastroenterol."},{"issue":"3","key":"54466_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76(3), 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"key":"54466_CR4","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro, V. et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57, 1826\u20131837 (2013).","journal-title":"Hepatology"},{"issue":"1","key":"54466_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem, R. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1), 52\u201364 (2010).","journal-title":"Gastroenterology"},{"issue":"2","key":"54466_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A El Fouly","year":"2015","unstructured":"El Fouly, A. et al. In intermediate stage hepatocellular carcinoma: radioembolization with Yttrium-90 or chemoembolization?. Liver Int. 35(2), 627\u2013635 (2015).","journal-title":"Liver Int."},{"issue":"13","key":"54466_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3390\/cancers17132254","volume":"17","author":"FM Sanai","year":"2025","unstructured":"Sanai, F. M. et al. Transarterial chemoembolization outperforms radioembolization in early- and intermediate-stage hepatocellular carcinoma: a multicenter retrospective study. Cancers (Basel) 17(13), 2254. https:\/\/doi.org\/10.3390\/cancers17132254 (2025).","journal-title":"Cancers (Basel)"},{"issue":"S1","key":"54466_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/HEP.0000000000001493","volume":"82","author":"FM Sanai","year":"2025","unstructured":"Sanai, F. M. et al. Predictors of outcome of transarterial locoregional therapies in unresectable hepatocellular carcinoma: a multicenter analysis. Hepatology 82(S1), S1\u2013S2308. https:\/\/doi.org\/10.1097\/HEP.0000000000001493 (2025).","journal-title":"Hepatology"},{"issue":"4","key":"54466_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/bjc.2016.423","volume":"116","author":"I Waked","year":"2017","unstructured":"Waked, I. et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br. J. Cancer 116(4), 448\u2013454 (2017).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"54466_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.31022","volume":"72","author":"G Han","year":"2020","unstructured":"Han, G. et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 72(1), 198\u2013212 (2020).","journal-title":"Hepatology"},{"issue":"5","key":"54466_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","volume":"70","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J. Hepatol. 70(5), 893\u2013903 (2019).","journal-title":"J. Hepatol."},{"key":"54466_CR12","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2147\/JHC.S544589","volume":"12","author":"QB Wang","year":"2025","unstructured":"Wang, Q. B. et al. Tumor compression of the hepatic or portal vein predicts the presence of microvascular invasion and satellite nodules in hepatocellular carcinoma: a retrospective study. J. Hepatocell. Carcinoma. 12, 2055\u201367 (2025).","journal-title":"J. Hepatocell. Carcinoma."},{"key":"54466_CR13","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/JHC.S556306","volume":"12","author":"WL Luo","year":"2025","unstructured":"Luo, W. L. et al. Impact of middle hepatic vein resection during hemihepatectomy on surgical outcomes and long-term prognosis in hepatocellular carcinoma: a retrospective study. J. Hepatocell. Carcinoma. 12, 2681\u201392 (2025).","journal-title":"J. Hepatocell. Carcinoma."},{"issue":"7","key":"54466_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","volume":"46","author":"G Maleux","year":"2023","unstructured":"Maleux, G. et al. Predictive factors for adverse event outcomes after transarterial radioembolization with Yttrium-90 resin microspheres in Europe: results from the prospective observational CIRT study. Cardiovasc. Intervent. Radiol. 46(7), 852\u2013867 (2023).","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"12","key":"54466_CR15","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/hep4.2087","volume":"6","author":"M Reincke","year":"2022","unstructured":"Reincke, M. et al. Hepatic decompensation after transarterial radioembolization in patients with hepatocellular carcinoma. Hepatol. Commun. 6(12), 3443\u201356 (2022).","journal-title":"Hepatol. Commun."},{"issue":"3","key":"54466_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4103\/sjg.sjg_343_24","volume":"31","author":"M Arabi","year":"2025","unstructured":"Arabi, M. et al. Identifying key predictors of mortality and liver decompensation in hepatocellular carcinoma patients treated with transarterial radioembolization. Saudi J. Gastroenterol. 31(3), 176\u2013184 (2025).","journal-title":"Saudi J. Gastroenterol."},{"issue":"2","key":"54466_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/lt.23552","volume":"19","author":"ER Garwood","year":"2013","unstructured":"Garwood, E. R., Fidelman, N., Hoch, S. E., Kerlan, R. K. Jr. & Yao, F. Y. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl. 19(2), 164\u201373 (2013).","journal-title":"Liver Transpl."},{"issue":"6","key":"54466_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2014the ALBI grade. J. Clin. Oncol. 33(6), 550\u20138 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"54466_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","volume":"66","author":"DJ Pinato","year":"2017","unstructured":"Pinato, D. J. et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J. Hepatol. 66(2), 338\u201346 (2017).","journal-title":"J. Hepatol."},{"issue":"1","key":"54466_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/jhep.2003.50315","volume":"38","author":"KP Moore","year":"2003","unstructured":"Moore, K. P. et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38(1), 258\u201366 (2003).","journal-title":"Hepatology"},{"issue":"5","key":"54466_CR21","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-K","volume":"31","author":"TS Lawrence","year":"1995","unstructured":"Lawrence, T. S. et al. Hepatic toxicity resulting from cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 31(5), 1237\u201348 (1995).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"54466_CR22","first-page":"1025","volume":"47","author":"B Sangro","year":"2008","unstructured":"Sangro, B. et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Hepatology. 47(3), 1025\u20131033 (2008).","journal-title":"Hepatology."},{"issue":"12","key":"54466_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.4254\/wjh.v6.i12.844","volume":"6","author":"N Imai","year":"2014","unstructured":"Imai, N. et al. Transarterial chemoembolization for hepatocellular carcinoma: a review of techniques. World J. Hepatol. 6(12), 844\u201350 (2014).","journal-title":"World J. Hepatol."},{"issue":"10","key":"54466_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4329\/wjr.v16.i10.512","volume":"16","author":"K Hao","year":"2024","unstructured":"Hao, K., Paik, A. J., Han, L. H. & Makary, M. S. Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. World J. Radiol. 16(10), 512\u2013527 (2024).","journal-title":"World J. Radiol."},{"issue":"3 Suppl","key":"54466_CR25","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan, C. C. et al. Radiation-associated liver injury. Int. J. Radiat. Oncol. Biol. Phys. 76(3 Suppl), S94-100 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"54466_CR26","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1111\/jgh.70098","volume":"40","author":"KA Ko","year":"2025","unstructured":"Ko, K. A. et al. Role of ALBI grade as a predictive factor for long\u2010term mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J. Gastroenterol. Hepatol. 40(11), 2758\u201366 (2025).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"54466_CR27","first-page":"110","volume":"12","author":"MA Khalid","year":"2019","unstructured":"Khalid, M. A. et al. To determine the prognostic value of the albumin\u2013bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. Gastroenterol. Hepatol. Bed Bench 12(2), 110\u2013115 (2019).","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"issue":"9","key":"54466_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/COC.0000000000000384","volume":"41","author":"B Gui","year":"2018","unstructured":"Gui, B. et al. Assessment of the albumin-bilirubin (ALBI) grade as a prognostic indicator for hepatocellular carcinoma patients treated with radioembolization. Am. J. Clin. Oncol. 41(9), 861\u20136 (2018).","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"54466_CR29","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","volume":"160","author":"DC Rockey","year":"2021","unstructured":"Rockey, D. C. & Friedman, S. L. Fibrosis regression after eradication of Hepatitis C virus: from bench to bedside. Gastroenterology 160(5), 1502\u201320 (2021).","journal-title":"Gastroenterology"},{"issue":"5","key":"54466_CR30","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","volume":"153","author":"S Lens","year":"2017","unstructured":"Lens, S. et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with Hepatitis C virus-associated cirrhosis. Gastroenterology 153(5), 1273\u201383 (2017).","journal-title":"Gastroenterology"},{"issue":"4","key":"54466_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer, M. et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J. Hepatol. 65(4), 692\u20139 (2016).","journal-title":"J. Hepatol."},{"issue":"3","key":"54466_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.30885","volume":"71","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer, M. et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology. 71(3), 1023\u201336 (2020).","journal-title":"Hepatology."},{"issue":"3","key":"54466_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","volume":"72","author":"M Pons","year":"2020","unstructured":"Pons, M. et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J. Hepatol. 72(3), 472\u201380 (2020).","journal-title":"J. Hepatol."},{"issue":"7","key":"54466_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1053\/j.gastro.2024.08.018","volume":"167","author":"M Premkumar","year":"2024","unstructured":"Premkumar, M. et al. Recompensation of chronic Hepatitis C-related decompensated cirrhosis following direct-acting antiviral therapy: prospective cohort study from a Hepatitis C virus elimination program. Gastroenterology. 167(7), 1429\u201345 (2024).","journal-title":"Gastroenterology."},{"issue":"3","key":"54466_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed, W., Shousha, H. & El-Kassas, M. Portal vein tumor thrombosis in hepatocellular carcinoma patients: is it the end?. Liver Res. 8(3), 141\u201351 (2024).","journal-title":"Liver Res."},{"key":"54466_CR36","doi-asserted-by":"publisher","first-page":"1714314","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li, J. et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk. Front Immunol. 17, 1714314 (2026).","journal-title":"Front Immunol."},{"issue":"1","key":"54466_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101664","volume":"8","author":"AG Singal","year":"2025","unstructured":"Singal, A. G., Garcia-Reyes, K., Kelley, R. K. & Kim, E. Impact of LEAP-012 and EMERALD-1 in the management of HCC. JHEP Rep. 8(1), 101664 (2025).","journal-title":"JHEP Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54466-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54466-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:04:16Z","timestamp":1786403056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54466-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54466"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54466-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sanai consults for, and is on the speakers\u2019 bureau of, Boston Scientific, Roche Pharmaceuticals, AstraZeneca, and Bayer-Schering. Dr. Alzanbagi is on the speakers\u2019 bureau of Boston Scientific and AstraZeneca. Dr. Albenmousa is on the speakers\u2019 bureau of Boston Scientific. Others have nothing to disclose.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The institutional review boards (IRBs) of the participating centers approved the study (Institutional Review Board, King Abdullah International Medical Research Center \u2013 Jeddah and Riyadh, study number NRJ24\/017\/8, approval No: 0000053724; Institutional Review Board, King Abdullah Medical City, study number 22-882; Research Advisory Council for King Faisal Specialist Hospital and Research Center, study number 2251061). All treatment procedures were carried out in accordance with local institutional regulations and protocols. As this was a retrospective study using de-identified data, the requirement for informed consent was waived by all IRBs of the participating centers in accordance with local regulations.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24789"}}